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 2
ABSTRACT 31 
The turnaround time of conventional methods used to detect Mycobacterium 32 
tuberculosis in sputum samples and to obtain drug susceptibility information is 33 
prolonged in many developing countries, including Panama, leading to delays in 34 
appropriate treatment initiation and continued transmission in the community. We 35 
evaluated the performance of the molecular line probe assay, Genotype MTBDRplus 36 
version 2.0 assay, in detecting M. tuberculosis complex directly from respiratory 37 
specimens in smear-positive TB cases in four different regions in Panama, as well as the 38 
most frequent mutations in genes conferring resistance to isoniazid (katG, inh-A) and 39 
rifampicin (rpoB).  Our results were confirmed by the nitrate reductase assay and 40 
genomic sequencing. M. tuberculosis complex was detected by Genotype MTBDRplus 41 
version 2.0 with 100% sensitivity and specificity.  The sensitivity and specificity for 42 
rifampicin resistance were 100% and 100%, respectively, and 90.7% and 100%, 43 
respectively, for isoniazid resistance.  Isoniazid monoresistance was detected in 5.2% of 44 
new cases.  Genotype MTBDRplus 2.0 is highly accurate in detecting M. tuberculosis 45 
complex from respiratory specimens, and is able to discriminate INH mono-resistant 46 
from MDR cases within 2 days.   47 
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INTRODUCTION 48 
Novel diagnostic tools and their timely implementation in endemic areas are 49 
required to make progress towards the goal of reducing the global burden of 50 
tuberculosis (TB) (1).  In 2008, the World Health Organization (WHO) recommended 51 
the use of molecular line probe assays (LPAs) for the rapid detection of multidrug-52 
resistant (MDR) TB, defined as TB resistant to the first-line drugs, isoniazid and 53 
rifampicin. Two years later, the WHO endorsed the use of Xpert MTB/RIF for the rapid 54 
detection of MDR TB directly in sputum samples (2); however, its relatively high cost 55 
has precluded its widespread use in resource-limited settings. The Genotype 56 
MTBDRplus 2.0 assay is one of the commercially available LPAs which became 57 
available in February 2007 (3). Although this assay has been evaluated and 58 
implemented in several countries, its utility has not been formally evaluated in 59 
intermediate TB prevalence settings in Central America.    60 
The primary tool for the diagnosis of pulmonary TB cases in Panama, as in 61 
many countries, is staining of sputum samples for acid-fast bacilli (AFB; Ziehl Neelsen 62 
method). The National Reference Laboratory of Panama (NRL) employs the Canetti 63 
multiple proportion method for drug susceptibility testing (DST). The sensitivity of 64 
sputum AFB staining is approximately 50%, and may be as low as 30% in HIV-infected 65 
patients (4, 5). Additionally, the turnaround time for DST is a minimum of 6 weeks.  66 
The limited sensitivity and long delay in these traditional diagnostic modalities promote 67 
the continued transmission of drug-susceptible and drug-resistant TB in the community 68 
(6). Only 113 MDR cases were reported officially in Panama between 2001-2013 (7), 69 
although these figures are likely a gross underestimate of the incidence of MDR TB 70 
since DST is not routinely performed unless suspected based on clinical grounds.  71 
 o
n
 Septem
ber 12, 2018 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
 4
The effective use of a molecular technique applied directly to sputum samples, 72 
with a rapid turnaround time, is needed to reduce transmission and avoid outbreaks of 73 
MDR TB among vulnerable populations (8). In this study, we evaluated and compared 74 
the sensitivity and specificity of the Genotype MTBDRplus 2.0 assay performed 75 
directly on AFB-positive respiratory specimens with conventional culture-based 76 
diagnostics and DST. Genomic sequencing of all isolates was performed to corroborate 77 
the LPA results. 78 
 79 
RESULTS  80 
Demographic data 81 
During the period December 2012 to December 2013, 68 respiratory smear-82 
positive samples were collected as part of routine TB diagnostic workup (Table 1).  The 83 
majority of samples were from the region of Colón (40/68; 58.8%) or the Panama city 84 
metropolitan area (23/68; 33.8%), and 5/68 (7.4%) were from San Miguelito.  The 85 
majority of samples (45/68; 66%) were from male subjects. The age range of subjects 86 
was 16 to 90 years, although there were two peaks in the age distribution (18-27 and 48-87 
57 years old), and the mean age was 42 + 17.13. Ten patients (14.7%) had a history of 88 
previous TB treatment, while 58 (85.3%) were new TB cases. Four subjects (5.8%) 89 
were HIV-infected, and 33 (48.5%) were HIV-uninfected, although the HIV status was 90 
unknown in 31 subjects (45.5%). 91 
 92 
Respiratory specimen characteristics 93 
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Refrigeration time of the samples varied from 1 to 40 days due to distance of 94 
some institutions to the NRL. A little less than half of the specimens (27.9%) had been 95 
refrigerated between 6 to 10 days before being processed. The remainder was processed 96 
immediately. Samples were classified as mucopurulent, bloody, mucous and salivary 97 
according to the Pan American Health Organization (PAHO) classification (9); the 98 
majority (37/68; 55%) was determined to be mucous.  The volume of expectorated 99 
specimens ranged from 0.5ml to 4ml, although 3 specimens derived from bronchial 100 
aspirates ranged from 5 to 10ml in volume. The most frequently collected volume 101 
(26/68; 38.2%) was 1 ml.  All samples were subjected to acid-fast smear examination, 102 
revealing a range of bacillary loads: scanty (7/68; 10.3%), 1+ (35/68; 51.5%), 2+ 103 
(13/68; 19.1%) and 3+ (13/68; 19.1%) (Figure 1). 104 
 105 
Characterization of the M. tuberculosis complex 106 
Of the 68 AFB smear-positive respiratory specimens, 54 positive cultures on 107 
Lowenstein Jensen agar were obtained and classified as M. tuberculosis using 108 
biochemical assays, including nitrate reduction, niacin production and catalase 109 
inhibition at 68ºC (10). These results were confirmed genetically using DNA 110 
sequencing.  In contrast, the Genotype MTBDRplus 2.0 assay identified M. tuberculosis 111 
complex in all 68 processed respiratory samples, including the 14 samples in which 112 
mycobacteria did not grow on solid agar.   113 
 114 
Drug susceptibility testing with nitrate reductase assay (NRA) 115 
The nitrate reductase assay is used to detect antibiotic resistance following 116 
addition of potassium nitrate (KNO3) 1 mg/ml in Lowenstein–Jensen medium, as the 117 
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 6
reduction of nitrate can be detected by the development of a reddish color after addition 118 
of the Griess reagent (11). The WHO recommends that the NRA be used directly on 119 
smear-positive sputum specimens or on M. tuberculosis isolates grown on solid agar 120 
(12). Since nitrate reduction is used as an indicator of growth rather than grossly visible 121 
colonies, the NRA reduces the turnaround time for DST compared to conventional 122 
methods.  123 
In the current study, all positive cultures were tested by NRA, yielding the 124 
following results: 4 were isoniazid mono-resistant, 1 was rifampicin mono-resistant, 6 125 
were MDR and 42 were susceptible to both drugs. However, bacilli were not cultivable 126 
in 14 samples.  Four of these smear-positive samples were obtained following initiation 127 
of treatment, and the remaining 10 isolates were refrigerated for a mean duration of 15.7 128 
days, perhaps contributing to reduced bacillary viability.  Of the 14 samples that did not 129 
have a reportable phenotypic DST result, Genotype MTBDRplus 2.0 detected 2 with 130 
rifampicin mono-resistance, while 12 were susceptible to both drugs.   131 
 132 
Drug susceptibility testing with GenoType MTBDRplus ver 2.0 133 
Genotype MTBDRplus 2.0 identified 5/68 (7.4%) isolates as MDR, 4/68 (5.8%) 134 
as isoniazid mono-resistant, and 4/68 (5.8%) as rifampicin mono-resistant. The C-15T 135 
inhA mutation was the only mutation detected in all 4 isoniazid mono-resistant isolates.  136 
Rifampicin mono-resistant samples displayed two types of mutations: rpoB gene 137 
mutations H526D (3/4) and S531L (1/4). In contrast, mutations detected in MDR 138 
isolates were: rpoB S531L/katG S315T (4/5), and rpoB S531L/inhA C-15T (1/5) (Table 139 
2).   140 
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Among the 42 culture-positive samples found to be drug-susceptible by NRA, 141 
Genotype MTBDRplus 2.0 did not detect any mutation in the hotspots of the genes 142 
rpoB, katG or inhA.  143 
Relative to conventional DST, the Genotype MTBDRplus 2.0 yielded a 144 
sensitivity, specificity, positive predictive value, and negative predictive value of 100%, 145 
100%, 100%, and 100% for rifampicin resistance. Conversely, the sensitivity, 146 
specificity, positive predictive value, and negative predictive value of the Genotype 147 
MTBDRplus 2.0 relative to DST were 90.9%, 100%, 100%, 50% for isoniazid 148 
resistance. 149 
 150 
Genomic sequencing  151 
In five samples the extracted DNA concentration was below the threshold to 152 
perform sequencing. Genomic sequencing was performed for all culture-positive 153 
samples revealing: 3 INH-monoresistant, 1 RIF-monoresistant and 4 MDR strains.  The 154 
sensitivity and specificity of Genotype MTBDRplus version 2.0 compared to genomic 155 
sequencing for isoniazid was 87.5% and 100%, respectively, and 100% and 100%, 156 
respectively, for rifampicin.  Table 3 shows the correlation between Genotype 157 
MTBDRplus 2.0, genomic sequencing and conventional DST.   158 
 159 
Discussion  160 
To our knowledge, our study is the first to evaluate the performance of the 161 
Genotype MTBDRplus 2.0 assay applied directly on respiratory specimens in Central 162 
America, a region of intermediate TB endemicity.  In Panama, AFB staining and 163 
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 8
culture-based DST remain the primary tools for the diagnosis of pulmonary TB and 164 
detection of drug resistance. Therefore, parameters such as quality of the specimen, as 165 
well as volume and storage time, are taken into consideration for interpreting 166 
microscopy and DST results (10).  Importantly, in the current study, the Genotype 167 
MTBDRplus 2.0 assay was able to correctly detect TB cases and drug resistance 168 
regardless of sample volume or refrigeration storage time, likely due to increased 169 
sensitivity of DNA amplification-based methods, as well as lack of requirement for the 170 
presence of viable and/or cultivable bacilli in respiratory specimens.   171 
Of the 10 patients with a prior history of TB treatment, 9 harbored isolates with 172 
resistance to at least one drug, while 1 was sensitive to both isoniazid and rifampicin. 173 
Five (56%) of these patients had a history of substance abuse, including cocaine, 174 
marijuana, and/or alcohol, and 2 patients were HIV-infected.  As in many parts of the 175 
world, in Panama drug-resistant TB is prevalent among the homeless and those with a 176 
history of illicit drug use, as these populations are less likely to adhere to medical 177 
treatment and are at increased for acquiring primary drug-resistant TB infection (13, 178 
14). 179 
Among newly diagnosed, culture-confirmed TB cases, one isolate (1.7%) was 180 
MDR and 5.2% (3/58) were found to have isoniazid mono-resistance. The prevalence of 181 
isoniazid-resistant TB among newly diagnosed cases ranges geographically from 5-25% 182 
(15). Although the treatment outcome for such cases remains unclear, several 183 
retrospective studies suggest that further drug resistance is promoted in the community 184 
when isoniazid resistance is not recognized and standard treatment is provided (16-19).  185 
Interestingly, the c-15t mutation, which is significantly less common than the katG 186 
S315T mutation in isoniazid-resistant isolates worldwide (20) and in Panama, was 187 
present in all 3 cases in our study, suggesting the possibility of recent transmission.  188 
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  In the current study, the sensitivity of the Genotype MTBDRplus version 2.0 189 
for isoniazid resistance (90.7%) was greater than in studies done prior to 2007 (21) 190 
likely because the newer version of the assay also analyzes the inhA locus in addition to 191 
katG.  The sensitivity of Genotype MTBDRplus 2.0 for isoniazid resistance might be 192 
further improved by including additional resistance mutations based on geographic 193 
distribution (22).   Knowledge of the precise mutation conferring resistance may be very 194 
useful clinically, particularly in the case of isoniazid, as the inhA c-15t mutation 195 
generally confers low-level resistance, which may be overcome with higher doses of 196 
isoniazid (23, 24).    Moreover, this version has been evaluated in smear-negative/culture 197 
positive specimens showing sensitivities between 58% to 76% (25, 26). 198 
The LPA and DST yielded concordant results in all 42 susceptible isolates.  On 199 
the other hand, LPA and DST yielded discordant results in two resistant cases.  Sample 200 
003-061 was reported as sensitive to isoniazid by Genotype MTBDRplus 2.0 and 201 
resistant by NRA, which was confirmed by Canetti’s multiple proportion method.  202 
Sequencing of this sample revealed the mutation Y337C in the katG gene. Enzymology 203 
studies show that this mutation confers resistance by reducing efficiency of INH radical 204 
formation while maintaining catalytic efficiency for its native catalase activity, similar 205 
to S315T (27). Although it is not a commonly recognized mutation (28), Y337C has 206 
been reported to confer INH resistance among non-clustered isolates (29).  Our previous 207 
studies revealed that approximately 16% of clustered MDR isolates in Panama over the 208 
past decade lacked mutations at the katG and inhA loci (30).  The second discordant 209 
case was isolate 044-04, which contained a c-15t mutation detected by LPA, although 210 
an indeterminate reaction was noted by NRA.  Canetti’s multiple proportion method 211 
yielded the growth of a single isoniazid-resistant colony. Sequencing of this sample 212 
confirmed the LPA result.  Interestingly, this sample was refrigerated for 18 days, 213 
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 10
suggesting there may have been loss of bacterial viability, potentially accounting for the 214 
false negative DST result. 215 
The ability to detect very few resistant bacilli in a sputum sample may represent 216 
an advantage of molecular drug susceptibility testing.  Although the current version of 217 
the Genotype MTBDRplus 2.0 assay still cannot detect all INH resistance-conferring 218 
mutations, it has a high sensitivity for detecting RIF resistance, and, therefore, for 219 
identifying MDR cases. Furthermore, the rapid turnaround time of 2 days in yielding 220 
TB drug susceptibility results as compared to 2-3 months for standard, culture-based 221 
DST methods is a major boon for, facilitating clinical decision-making and the selection 222 
of appropriate anti-tubercular therapy in real time. 223 
 224 
Materials and methods 225 
Ethics statement 226 
This study was approved by the Bioethics Committee of Panama. 227 
 228 
Respiratory samples  229 
68 smear-positive respiratory specimens were collected at four different 230 
hospitals from three health regions in Panamá with a high prevalence of the LAM9-c1 231 
MDR isolates in the past decade (6): Manuel Amador Guerrero Hospital (Mariela 232 
Vergara; Colón Region); Nuevo Veranillo Health Center (Silvana Campos; San 233 
Miguelito Region); and Complejo Hospitalario Metropolitano Dr. Arnulfo Arias Madrid 234 
(Berta Marshall), 24 de Diciembre Hospital (Julio Dominguez), Pueblo Nuevo Health 235 
Center (Delsa Pimentel) and Santo Tomás Hospital (Erika Santigo) (all in Panamá 236 
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Metro Region). Most respiratory specimens were from pre-treatment cases collected 237 
between December 2012 to December 2013.  Due to financial constraints, smear-238 
negative samples were not evaluated.   239 
 240 
Sample processing and culture  241 
Direct smears were prepared from the specimens using Ziehl-Neelsen staining.  242 
Smears were read and interpreted in accordance with PAHO guidelines (9). Specimens 243 
were decontaminated with the standard NALC-NaOH method (9) and the pellet was 244 
suspended in 1.0ml of phosphate buffer (pH 6.8). This was followed by inoculation on 245 
Lowenstein Jensen agar and the residual portion of decontaminated sample was used to 246 
perform genomic extraction using the Genolyse kit. 247 
 248 
Biochemical characterization and drug susceptibility testing 249 
After incubation on Lowenstein Jensen agar, isolates were classified as M. 250 
tuberculosis using biochemical assays, including nitrate reduction, niacin production, 251 
and catalase inhibition at 68ºC. DST was performed on all isolates using NRA and the 252 
following critical concentrations of antibiotics: 0.2 µg/ml isoniazid and 40 µg/ml 253 
rifampicin (10, 11).  254 
In cases yielding discordant results between the LPA and NRA assays, Canetti’s 255 
multiple proportions method was performed according to the Panama National TB 256 
Control Program guidelines (10), using the same antibiotic concentrations as the NRA 257 
assay. 258 
 259 
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GenoType MTBDRplus 2.0 260 
Genotype MTBDRplus version 2.0 test (Hain Lifescience, Germany) is based on 261 
the DNA STRIP technology consisting of three steps: DNA extraction, multiplex 262 
amplification with biotinylated primers and reverse hybridization as per manufacturer’s 263 
instructions (3).  DNA extraction was performed with Genolyse kit in three steps: 264 
centrifugation, lysis at 95ºC and neutralization.  The following amplification protocol 265 
was used for clinical specimens: one cycle of 15 min at 95ºC, followed by 20 cycles of 266 
30 sec at 95ºC and 2 min at 65ºC, followed by 30 cycles of 25 sec at 95ºC, 40 sec at 267 
50ºC and 40 sec at 70ºC, ending with 1 cycle of 8 min at 70ºC.  Reverse hybridization 268 
was performed with an automated hybridization machine: Auto-Lipa 48 (Innogenetics) 269 
was used with the reagents provided according to Genotype MTBDRplus ver 2.0 kit for 270 
the hybridization procedure (3).  Interpretation was done according to the guide 271 
included in the Genotype MTBDRplus kit. The absence of a wild type (WT) band and 272 
the presence of a mutant band (MUT) for a specific gene on the strip implied resistance.  273 
 274 
Genome Sequencing  275 
Mycobacterial isolates were sequenced on an Illumina HiSeq 2500 instrument 276 
using a paired-end (PE) sequencing strategy.  DNA samples were extracted from 277 
colonies using the QIAamp DNA Mini Kit, sheared into ~250 bp fragments using a 278 
Covaris sonicator (Covaris, Inc.), and prepared using the standard whole-genome DNA 279 
sequencing sample preparation kit (Illumina, Inc.).  Paired-end reads of length 72 bp 280 
were collected.  Base-calling was performed using Online Base-Caller (OLB) v. 1.9.3 281 
(Illumina, Inc.).  Genome assembly was performed using custom software that 282 
implements a comparative assembly approach (31) by aligning reads to the genome 283 
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sequence of M. tuberculosis H37Rv (NC_000962.2).  Mean depth of coverage over the 284 
genome averaged 68-fold over all samples (range 9.8-125.6).  A local contig-building 285 
algorithm was used to identify indels (insertions or deletions) in regions where coverage 286 
spiked low. 287 
  288 
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Table 1: Demographic Data 306 
 307 
 308 
 309 
  310 
 311 
 312 
 313 
  314 
Demographic data  n=68 (%) 
Age 
Mean years (range) 42 (16-90) 
Sex 
Female 23 (33.8) 
Male 45 (66.1) 
TB history 
New cases 58 (85.3) 
Retreatment 10 (14.7) 
HIV-infected 
Yes  4 (5.8) 
No 33 (48.5) 
Unknown 31 (45.5) 
Health region 
Colón 40 (58.8) 
Panamá Metro 23 (33.8) 
San Miguelito  5 (7.4) 
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Table 2. Band patterns of drug-resistant Mycobacterium tuberculosis isolates using 315 
Genotype MTBDRplus 2.0 316 
 
Gene 
 
Band 
 
Gene region or 
mutation 
 
MDR 
n=5 (%) 
INH 
Monoresistant 
n=4 (%) 
RIF  
Monoresistant
n=4 (%) 
rpoB WT7 526 − 529 0 (0) 0 (0) 3 (75) 
 WT8 530 − 533 5 (100) 0 (0) 1 (25)
 MUT2B H526D 0 (0) 0 (0) 3 (75) 
 MUT3 S531L 5 (100) 0 (0) 1 (25)
katG WT 315 4 (80) 0 (0) 0 (0) 
 MUT1 S315T1 4 (80) 0 (0) 0 (0) 
inhA WT1 -15/-16 1 (20) 4 (100) 0 (0)
 MUT1 C15T 1 (20) 4 (100) 0 (0) 
  317 
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Table 3. Summary of results of RIF and INH resistance by Genotype MTBDRplus, 318 
Sequencing and conventional DST 319 
R: resistant; CONT: contamination; LC: low concentration of DNA; NG: No growth; 320 
W: weak reaction.  321 
ID 
SAMPLE 
GENOTYPE 
MTBDRPLUS            
GENOMIC 
SEQUENCING           
NRA-DST                 
RIFR INHR RIFR INHR RIFR INHR 
003-061 S531L  S531L Y337C R R 
006-02 S531L C-15T S531L C-15T R R 
011-02 H526D  CONT CONT CONT CONT 
044-04  C-15T  C-15T S Rw 
049-01  C-15T LC LC S R 
058-01 S531L S315T LC LC R R 
098-03 H526D  H526D  R S 
113-061 S531L S315T S531L S315T R R 
121-01 S531L S315T S531L S315T R R 
147-04  C-15T  C-15T S R 
156-061 S531L S315T LC LC         R         R 
241-01 H526D  NG NG NG NG 
242-062  C-15T  C-15T S R 
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Figure legends 322 
Figure 1. Respiratory specimen characteristics.  Samples were classified according to 323 
the Pan American Health Organization (PAHO) classification (10). Colors refer to the 324 
proportion of specimens in each quality category, which are graded as scanty, 1+, 2+, or 325 
3+ by acid-fast staining.  326 
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